Yasmeen Rahimi, Ph.D.

Yasmeen Rahimi is a managing director and senior research analyst at Piper Sandler covering biotechnology. Prior to joining Piper Sandler in July 2020, Rahimi was a senior research analyst and co-head of biotechnology equity research team at ROTH Capital Partners. Before that, she worked as an equity research associate at H.C. Wainwright & Co. and Guggenheim Securities. Prior to making the transition to Wall Street, Rahimi was a research scientist at Shire Pharmaceuticals where she developed biomarker strategies for a number of rare disease programs; she has extensive expertise in liver metabolism. Rahimi trained as a postdoctoral fellow at Yale University in the laboratory of Gerald Shulman after completing her Ph.D. from Indiana University School of Medicine. In addition, she has a M.S. in bioanalytical chemistry from Purdue University and a joint B.A. in German and chemistry from Butler University.

Universe Coverage

Biotechnology
SLRN	ACELYRIN, Inc.
ALGS	Aligos Therapeutics, Inc.
ALLK	Allakos, Inc.
ALT	Altimmune, Inc.
ANAB	AnaptysBio, Inc.
ARCT	Arcturus Therapeutics Holdings, Inc.
LIFE	aTyr Pharma, Inc.
BNTC	Benitec Biopharma, Inc.
CRNX	Crinetics Pharmaceuticals, Inc.
CYTK	Cytokinetics, Incorporated
DSGN	Design Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
GOSS	Gossamer Bio
IMUX	Immunic, Inc.
IMVT	Immunovant, Inc.
KRRO	Korro Bio, Inc.
LXRX	Lexicon Pharmaceuticals, Inc.
LUMO	Lumos Pharma, Inc.
MDGL	Madrigal Pharmaceuticals, Inc.
NKTR	Nektar Therapeutics
NAMS	NewAmsterdam Pharma Co. NV
PLRX	Pliant Therapeutics, Inc.
PRAX	Praxis Precision Medicines, Inc.
PRTA	Prothena Corporation plc
SAGE	Sage Therapeutics, Inc.
SGMT	Sagimet Biosciences, Inc.
SVRA	Savara, Inc.
SLNO	Soleno Therapeutics, Inc.
GPCR	Structure Therapeutics, Inc.
TECX	Tectonic Therapeutic Inc.
TNYA	Tenaya Therapeutics, Inc.
TRML	Tourmaline Bio, Inc.
UNCY	Unicycive Therapeutics, Inc.
UPB	Upstream Bio, Inc.
VTYX	Ventyx Biosciences, Inc.
VRNA	Verona Pharma Plc
ZURA	Zura Bio Ltd.